Real World of Ophthalmology

Real World of Ophthalmology

Source:

Jackson M. Drugs and devices that improved my surgical outcomes. Presented at: Real World Ophthalmology; April 2, 2022 (virtual meeting).

Disclosures: Jackson reports consulting and speaking for Ocular Therapeutix and Omeros/Rayner.
April 20, 2022
1 min read
Save

Innovative technology can benefit ophthalmology practices

Source:

Jackson M. Drugs and devices that improved my surgical outcomes. Presented at: Real World Ophthalmology; April 2, 2022 (virtual meeting).

Disclosures: Jackson reports consulting and speaking for Ocular Therapeutix and Omeros/Rayner.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Ophthalmologists can improve surgical outcomes by incorporating new drugs and devices into their practices, according to a presentation at Real World Ophthalmology.

Mitchell A. Jackson, MD, said three innovations — Omidria (phenylephrine 1% and ketorolac 0.3% intraocular solution, Omeros/Rayner), Dextenza (dexamethasone ophthalmic insert 0.4 mg, Ocular Therapeutix) and Zepto (Centricity Vision) — have helped him do just that.

Omidria is indicated for maintaining pupil size by preventing intraoperative miosis, as well as reducing postoperative ocular pain.

“We know what happens when you get miosis. The case becomes impossible,” Jackson said. “If you can prevent it, you don’t have to manage it.”

Jackson said phase 3 studies have shown that if patients are on Omidria at the time of lens implantation, 83% will maintain a pupil size of at least 6 mm. It also reduces the need for pupil-expanding devices, which can create stress and trauma for the patient’s iris.

Dextenza is a corticosteroid insert that is indicated for the treatment of postoperative ocular inflammation and itching associated with allergic conjunctivitis. It provides sustained release of dexamethasone 0.4 mg for up to 30 days.

Jackson said Dextenza helps improve compliance because patients do not need to rely on drops.

“What I like about it in the real world is it really enhances my ocular surface,” he said. “It’s a great benefit for my premium IOL patients, and it reduces the need for one additional drop.”

Jackson said Zepto is a handheld device that helps perform consistent, uniform capsulotomies, reducing the risk for IOL movement and supporting refractive stability.

“It happens very quickly,” he said. “You get an automated and centrated capsulotomy, which is going to be very good for lens placement.”